Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.

The researched and other already registered new combined pharmaceutical products are innovative scientific solutions developed by Tchaikapharma and are extensively prescribed by doctors and are met with a wide satisfaction by patients – in Bulgaria and a number of pharmaceutical markets in the EU.

On 20 August 2018, the Food and Drug Administration of the USA made a proposal for simplification of the registration procedure for exactly this kind of pharmaceutical combinations and the Administration described them as “complex” and accepted their innovative combined effect and high efficacy, which cannot be found in the already known mono-component generic medications.

Tchaikapharma’s laboratories are completing the development, and more importantly, are about to finish – within the next 18 months – the clinical trials of the three-component pharmaceutical products for the treatment of cardiovascular disease and diabetes.

Cardiovascular diseases and diabetes are the chronicle conditions with the highest morbidity and longest duration in the EU countries, which lead to acute complications such as myocardial infarction, stroke and other severe life-threatening events.

Tchaikapharma International Press Center